SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022 and 2023

Yaniv Lustig; Michal Canetti; Victoria Indenbaum; Yovel Peretz; Yael Weiss-Ottolenghi; Ili Margalit; Keren Asraf; Tal Levin; Neta Zuckerman; Enosh Tomer; Michal Mandelboim; Ram Doolman; Noam Barda; Gili Regev-Yochay

doi:10.3201/eid3005.231739

SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022 and 2023

Yaniv Lustig
, Michal Canetti
, Victoria Indenbaum
, Yovel Peretz
, Yael Weiss-Ottolenghi
, Ili Margalit
, Keren Asraf
, Tal Levin
, Neta Zuckerman
, Enosh Tomer
, Michal Mandelboim
, Ram Doolman
, Noam Barda
, Gili Regev-Yochay

Department of Epidemiology, Biostatistics and Community Health Sciences

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Although a vaccine against SARS-CoV-2 Omicron-XBB.1.5 variant is available worldwide and recent infection is protective, the lack of recorded infection data highlights the need to assess variant-specific antibody neutralization levels. We analyzed IgG levels against receptor-binding domain–specific SARS-CoV-2 ancestral strain as a correlate for high neutralizing titers against XBB variants.

Original language	English
Pages (from-to)	1050-1052
Number of pages	3
Journal	Emerging Infectious Diseases
Volume	30
Issue number	5
DOIs	https://doi.org/10.3201/eid3005.231739
State	Published - 1 May 2024

ASJC Scopus subject areas

Epidemiology
Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3201/eid3005.231739

Cite this

Lustig, Y., Canetti, M., Indenbaum, V., Peretz, Y., Weiss-Ottolenghi, Y., Margalit, I., Asraf, K., Levin, T., Zuckerman, N., Tomer, E., Mandelboim, M., Doolman, R., Barda, N., & Regev-Yochay, G. (2024). SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022 and 2023. Emerging Infectious Diseases, 30(5), 1050-1052. https://doi.org/10.3201/eid3005.231739

@article{4bb01df3824a4b608fd1f7000ef971d9,

title = "SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022 and 2023",

abstract = "Although a vaccine against SARS-CoV-2 Omicron-XBB.1.5 variant is available worldwide and recent infection is protective, the lack of recorded infection data highlights the need to assess variant-specific antibody neutralization levels. We analyzed IgG levels against receptor-binding domain–specific SARS-CoV-2 ancestral strain as a correlate for high neutralizing titers against XBB variants.",

author = "Yaniv Lustig and Michal Canetti and Victoria Indenbaum and Yovel Peretz and Yael Weiss-Ottolenghi and Ili Margalit and Keren Asraf and Tal Levin and Neta Zuckerman and Enosh Tomer and Michal Mandelboim and Ram Doolman and Noam Barda and Gili Regev-Yochay",

year = "2024",

month = may,

day = "1",

doi = "10.3201/eid3005.231739",

language = "English",

volume = "30",

pages = "1050--1052",

journal = "Emerging Infectious Diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "5",

}

Lustig, Y, Canetti, M, Indenbaum, V, Peretz, Y, Weiss-Ottolenghi, Y, Margalit, I, Asraf, K, Levin, T, Zuckerman, N, Tomer, E, Mandelboim, M, Doolman, R, Barda, N & Regev-Yochay, G 2024, 'SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022 and 2023', Emerging Infectious Diseases, vol. 30, no. 5, pp. 1050-1052. https://doi.org/10.3201/eid3005.231739

TY - JOUR

T1 - SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022 and 2023

AU - Lustig, Yaniv

AU - Canetti, Michal

AU - Indenbaum, Victoria

AU - Peretz, Yovel

AU - Weiss-Ottolenghi, Yael

AU - Margalit, Ili

AU - Asraf, Keren

AU - Levin, Tal

AU - Zuckerman, Neta

AU - Tomer, Enosh

AU - Mandelboim, Michal

AU - Doolman, Ram

AU - Barda, Noam

AU - Regev-Yochay, Gili

PY - 2024/5/1

Y1 - 2024/5/1

N2 - Although a vaccine against SARS-CoV-2 Omicron-XBB.1.5 variant is available worldwide and recent infection is protective, the lack of recorded infection data highlights the need to assess variant-specific antibody neutralization levels. We analyzed IgG levels against receptor-binding domain–specific SARS-CoV-2 ancestral strain as a correlate for high neutralizing titers against XBB variants.

AB - Although a vaccine against SARS-CoV-2 Omicron-XBB.1.5 variant is available worldwide and recent infection is protective, the lack of recorded infection data highlights the need to assess variant-specific antibody neutralization levels. We analyzed IgG levels against receptor-binding domain–specific SARS-CoV-2 ancestral strain as a correlate for high neutralizing titers against XBB variants.

UR - https://www.scopus.com/pages/publications/85191460821

U2 - 10.3201/eid3005.231739

DO - 10.3201/eid3005.231739

M3 - Article

C2 - 38666742

AN - SCOPUS:85191460821

SN - 1080-6040

VL - 30

SP - 1050

EP - 1052

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

IS - 5

ER -

SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022 and 2023

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this